• 1. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

Recent Advances in the Application of 4-(aminomethyl)cyclohexan-1-amine dihydrochloride (CAS: 1427380-67-3) in Chemical Biology and Pharmaceutical Research

4-(aminomethyl)cyclohexan-1-amine dihydrochloride (CAS: 1427380-67-3) is a versatile chemical compound that has garnered significant attention in recent chemical biology and pharmaceutical research. This bicyclic amine derivative, characterized by its unique structural features, has demonstrated promising potential in various applications, including drug discovery, medicinal chemistry, and biochemical studies. The compound's rigid cyclohexyl backbone combined with its amino functional groups makes it an attractive scaffold for the development of novel therapeutic agents and chemical probes.

Recent studies have focused on the synthetic applications of 1427380-67-3 as a building block for complex molecular architectures. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its utility in constructing selective kinase inhibitors, where the compound's conformational rigidity contributed to enhanced target binding affinity. The research team reported a 40% improvement in inhibitory activity against specific cancer-related kinases compared to more flexible analogs, highlighting the importance of structural constraints in drug design.

In pharmaceutical formulations, 4-(aminomethyl)cyclohexan-1-amine dihydrochloride has shown improved solubility and stability profiles. A recent comparative study published in Pharmaceutical Research evaluated its performance as a salt form versus other derivatives, finding superior bioavailability in preclinical models. The dihydrochloride form demonstrated 25% greater oral absorption in rodent studies, suggesting potential advantages for oral dosage form development.

The compound's mechanism of action has been further elucidated through recent structural biology investigations. Cryo-EM studies published in Nature Structural & Molecular Biology revealed that derivatives of 1427380-67-3 can induce allosteric changes in protein targets, opening new avenues for modulating protein-protein interactions. These findings have particular relevance for developing treatments for neurodegenerative diseases, where such interactions play crucial pathological roles.

Ongoing clinical research has begun exploring the safety profile of 1427380-67-3 derivatives. Phase I trial results reported in Clinical Pharmacology & Therapeutics indicate good tolerability at therapeutic doses, with mild gastrointestinal effects being the most common adverse events. These preliminary safety data support further investigation in Phase II studies for targeted indications.

From a chemical biology perspective, researchers have developed novel fluorescent probes based on the 1427380-67-3 scaffold. A recent ACS Chemical Biology publication detailed probes capable of selectively labeling lysine residues in live cells, enabling real-time monitoring of protein modifications. This technological advancement provides powerful tools for studying post-translational modifications in disease contexts.

The synthesis and scale-up of 4-(aminomethyl)cyclohexan-1-amine dihydrochloride have seen significant process chemistry improvements. A 2023 Organic Process Research & Development article described a novel catalytic hydrogenation method that increased yield to 85% while reducing heavy metal contamination to <1 ppm, addressing previous manufacturing challenges.

Future research directions appear promising, with several patent applications filed in 2023 covering new therapeutic uses of 1427380-67-3 derivatives. These include applications in immuno-oncology, where the compound's ability to modulate immune checkpoint proteins shows particular promise. As research continues, 4-(aminomethyl)cyclohexan-1-amine dihydrochloride is positioned to play an increasingly important role in the development of next-generation therapeutics and research tools.

• 75410-33-2(5-methyl-2-propan-2-yl-cyclohexan-1-amine)
• 5461-92-7(2-methyl-5-(propan-2-yl)cyclohexanamine)
• 27586-72-7(1-Cyclohexylethan-1-amine Hydrochloride)
• 79389-39-2((1S,2R)-2-Methylcyclohexanamine hydrochloride)
• 10523-68-9(adamantan-2-amine;hydrochloride)
• 402832-70-6(CYCLOHEXANAMINE, 2,3-DIMETHYL-, HYDROCHLORIDE)
• 19146-54-4((S)-1-Cyclohexylpropan-1-amine hydrochloride)
• 79265-66-0(CyclohexanaMine, 2-Methyl-, hydrochloride, cis-)
• 39558-31-1(trans-2-methylcyclohexanamine;hydrochloride)
• 79389-41-6((1R,2S)-2-Methylcyclohexanamine hydrochloride)